Erasca Faces Class Action Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: Globenewswire
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Erasca, Inc. for violations of the Securities Exchange Act from January 14, 2025, to April 26, 2026, urging affected investors to contact the firm by August 10, 2026.
- False Statement Allegations: The complaint alleges that Erasca made misleading statements regarding its ERAS-0015 preclinical data, improperly comparing it to Revolution Medicines, which risks patent violations and misled investors about the company's prospects.
- Loss Recovery Opportunity: Investors are encouraged to join the lawsuit to recover losses, with Schall Law Firm specializing in securities class actions and offering free consultations to help affected shareholders understand their rights.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 17.920
Low
2.00
Averages
5.50
High
11.00
Current: 17.920
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Erasca, Inc. for violations of the Securities Exchange Act from January 14, 2025, to April 26, 2026, urging affected investors to contact the firm by August 10, 2026, to participate.
- False Statement Allegations: The complaint alleges that Erasca made misleading statements regarding its ERAS-0015 preclinical data, improperly comparing it to Revolution Medicines, which undermined the validity of its optimistic claims throughout the class period.
- Investor Losses: As the market became aware of the truth regarding Erasca, investors suffered significant losses, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit to recover damages, highlighting serious deficiencies in the company's disclosure practices.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, urging affected investors to take action before the class action is certified to ensure their rights are protected.
See More
Erasca, Inc. Shareholder Class Action Reminder
- Class Action Initiated: Robbins LLP reminds all shareholders who purchased Erasca, Inc. (NASDAQ:ERAS) securities between January 14, 2025, and April 26, 2026, that a class action has been filed to protect investor rights and seek compensation.
- Patent Risk Disclosure: The lawsuit alleges that Erasca failed to disclose that its ERAS-0015 preclinical data was based on improper comparisons, potentially infringing Revolution Medicines, Inc.'s patents and trade secrets, which could severely impact the company's reputation and shareholder confidence.
- Stock Price Volatility: Following the disclosure of a legal letter from RevMed on April 27, 2026, Erasca's stock price plummeted from $21.49 per share on April 24, 2026, to $19.15 per share, indicating the market's sensitivity to the company's legal risks.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by August 10, 2026, indicating their representative role in the litigation, while those who choose not to participate can remain absent class members and retain their rights to recovery.
See More
Erasca Faces Class Action Lawsuit Risks
- Class Action Initiation: Purchasers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek lead plaintiff status in a class action lawsuit alleging violations of the Securities Exchange Act of 1934 by the company and its executives.
- Patent Infringement Allegations: The lawsuit claims that Erasca's preclinical data for ERAS-0015 was based on improper comparisons, potentially exposing the company to patent and trade secret risks, which could adversely affect its reputation and future product development.
- Stock Price Volatility: Following the disclosure of a patent infringement letter from Revolution Medicines on April 27, 2026, Erasca's stock price fell nearly 11%, and subsequent clinical data release led to an additional decline of over 48%, indicating a severe loss of market confidence in its product.
- Legal Process Implications: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Erasca stock during the class period can apply to be the lead plaintiff, representing other shareholders in the lawsuit, which may impact the company's future legal and financial standing.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization and severely undermining investor confidence.
- Legal Action: The securities class action aims to represent investors who purchased Erasca shares between January 14, 2025, and April 26, 2026, alleging violations of federal securities laws, which could lead to further legal liabilities for the company.
- Improper Comparison Allegations: The lawsuit claims that Erasca improperly compared its ERAS-0015 treatment to RevMed's RMC-6236, potentially jeopardizing the validity of its intellectual property claims and affecting its competitive standing in the market.
- Patient Safety Incident: Following the lawsuit's revelations, Erasca disclosed that a patient treated with ERAS-0015 suffered an adverse event and died a month later, intensifying market concerns regarding the safety profile of its product.
See More
Reminder for Erasca Shareholder Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the Erasca class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected parties to participate in the litigation.
- Legal Violations Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate ERAS-0015 throughout the class period, resulting in investor losses when the truth emerged.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record in the field, thereby enhancing investor confidence in its representation.
See More
Multiple Companies Face Class Action Lawsuits
- Erasca Lawsuit Overview: Erasca, Inc. (NASDAQ:ERAS) faces a class action lawsuit for the period from January 14, 2025, to April 26, 2026, alleging that the company failed to disclose improper comparisons in its ERAS-0015 preclinical data, misleading investors about its prospects, with a lead plaintiff motion deadline of August 10, 2026.
- Nano-X Operational Issues: Nano-X Imaging Ltd. (NASDAQ:NNOX) is under scrutiny in a class action lawsuit covering March 31, 2025, to April 17, 2026, for overstating operational efficiency and product demand, while actually facing increased operating expenses and cash burn, requiring lead plaintiff motions by August 11, 2026.
- Microsoft Product Deficiencies: Microsoft Corporation (NASDAQ:MSFT) is implicated in a class action lawsuit for the period from May 1, 2025, to January 28, 2026, alleging significant issues with its Copilot product line, including poor brand positioning and user experience, leading to a decline in market share, with a lead plaintiff motion deadline of August 11, 2026.
- Black Rock Coffee Expansion Risks: Black Rock Coffee Bar, Inc. (NASDAQ:BRCB) faces a class action lawsuit for the period from September 12, 2025, to May 12, 2026, claiming that new store openings cannibalized existing services and revenue, with a lead plaintiff motion deadline of August 17, 2026.
See More
Erasca Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Erasca, Inc. for violations of the Securities Exchange Act from January 14, 2025, to April 26, 2026, urging affected investors to contact the firm by August 10, 2026, to participate.
- False Statement Allegations: The complaint alleges that Erasca made misleading statements regarding its ERAS-0015 preclinical data, improperly comparing it to Revolution Medicines, which undermined the validity of its optimistic claims throughout the class period.
- Investor Losses: As the market became aware of the truth regarding Erasca, investors suffered significant losses, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit to recover damages, highlighting serious deficiencies in the company's disclosure practices.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, urging affected investors to take action before the class action is certified to ensure their rights are protected.
See More
Erasca, Inc. Shareholder Class Action Reminder
- Class Action Initiated: Robbins LLP reminds all shareholders who purchased Erasca, Inc. (NASDAQ:ERAS) securities between January 14, 2025, and April 26, 2026, that a class action has been filed to protect investor rights and seek compensation.
- Patent Risk Disclosure: The lawsuit alleges that Erasca failed to disclose that its ERAS-0015 preclinical data was based on improper comparisons, potentially infringing Revolution Medicines, Inc.'s patents and trade secrets, which could severely impact the company's reputation and shareholder confidence.
- Stock Price Volatility: Following the disclosure of a legal letter from RevMed on April 27, 2026, Erasca's stock price plummeted from $21.49 per share on April 24, 2026, to $19.15 per share, indicating the market's sensitivity to the company's legal risks.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by August 10, 2026, indicating their representative role in the litigation, while those who choose not to participate can remain absent class members and retain their rights to recovery.
See More
Erasca Faces Class Action Lawsuit Risks
- Class Action Initiation: Purchasers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek lead plaintiff status in a class action lawsuit alleging violations of the Securities Exchange Act of 1934 by the company and its executives.
- Patent Infringement Allegations: The lawsuit claims that Erasca's preclinical data for ERAS-0015 was based on improper comparisons, potentially exposing the company to patent and trade secret risks, which could adversely affect its reputation and future product development.
- Stock Price Volatility: Following the disclosure of a patent infringement letter from Revolution Medicines on April 27, 2026, Erasca's stock price fell nearly 11%, and subsequent clinical data release led to an additional decline of over 48%, indicating a severe loss of market confidence in its product.
- Legal Process Implications: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Erasca stock during the class period can apply to be the lead plaintiff, representing other shareholders in the lawsuit, which may impact the company's future legal and financial standing.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization and severely undermining investor confidence.
- Legal Action: The securities class action aims to represent investors who purchased Erasca shares between January 14, 2025, and April 26, 2026, alleging violations of federal securities laws, which could lead to further legal liabilities for the company.
- Improper Comparison Allegations: The lawsuit claims that Erasca improperly compared its ERAS-0015 treatment to RevMed's RMC-6236, potentially jeopardizing the validity of its intellectual property claims and affecting its competitive standing in the market.
- Patient Safety Incident: Following the lawsuit's revelations, Erasca disclosed that a patient treated with ERAS-0015 suffered an adverse event and died a month later, intensifying market concerns regarding the safety profile of its product.
See More
Reminder for Erasca Shareholder Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased Erasca, Inc. (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the Erasca class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected parties to participate in the litigation.
- Legal Violations Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate ERAS-0015 throughout the class period, resulting in investor losses when the truth emerged.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record in the field, thereby enhancing investor confidence in its representation.
See More
Multiple Companies Face Class Action Lawsuits
- Erasca Lawsuit Overview: Erasca, Inc. (NASDAQ:ERAS) faces a class action lawsuit for the period from January 14, 2025, to April 26, 2026, alleging that the company failed to disclose improper comparisons in its ERAS-0015 preclinical data, misleading investors about its prospects, with a lead plaintiff motion deadline of August 10, 2026.
- Nano-X Operational Issues: Nano-X Imaging Ltd. (NASDAQ:NNOX) is under scrutiny in a class action lawsuit covering March 31, 2025, to April 17, 2026, for overstating operational efficiency and product demand, while actually facing increased operating expenses and cash burn, requiring lead plaintiff motions by August 11, 2026.
- Microsoft Product Deficiencies: Microsoft Corporation (NASDAQ:MSFT) is implicated in a class action lawsuit for the period from May 1, 2025, to January 28, 2026, alleging significant issues with its Copilot product line, including poor brand positioning and user experience, leading to a decline in market share, with a lead plaintiff motion deadline of August 11, 2026.
- Black Rock Coffee Expansion Risks: Black Rock Coffee Bar, Inc. (NASDAQ:BRCB) faces a class action lawsuit for the period from September 12, 2025, to May 12, 2026, claiming that new store openings cannibalized existing services and revenue, with a lead plaintiff motion deadline of August 17, 2026.
See More
